Singapoo - Kiingereza - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - recombinant cholera toxin b subunit (rctb); vibrio cholerae o1 inaba classic strain (heat inactivated); vibrio cholerae o1 inaba el tor strain (formalin inactivated); vibrio cholerae o1 ogawa classic strain (formalin inactivated); vibrio cholerae o1 ogawa classic strain (heat inactivated) - suspension - 1 mg/dose - recombinant cholera toxin b subunit (rctb) 1 mg/dose; vibrio cholerae o1 inaba classic strain (heat inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 inaba el tor strain (formalin inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 ogawa classic strain (formalin inactivated) 31.25 x 10^9 bacteria; vibrio cholerae o1 ogawa classic strain (heat inactivated) 31.25 x 10^9 bacteria

Marekani - Kiingereza - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated) (unii: au5c98u4bb) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:c46xjt9fq9), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (formaldehyde inactivated) (unii: f5qv7af326) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:n969qk7xd2), influenza b virus b/austria/1359417/2021 bvr-26 antigen - fluad quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. fluad quadrivalent is approved for use in persons 65 years of age and older. this indication is approved under accelerated approval based on the immune response elicited by fluad quadrivalent [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. do not administer fluad quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad quadrivalent is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad quadrivalent in pregnancy. there were no development

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - amphotericin b; neomycin; polymixin b; feline leukaemia virus - inactivated; thiomersal - misc. vaccines or anti sera - amphotericin b antibiotic active 0.0 undefined; neomycin antibiotic active 0.0 undefined; polymixin b antibiotic active 0.0 undefined; feline leukaemia virus - inactivated vaccine-viral active 0.0 undefined; thiomersal mercury other 0.0 undefined - immunotherapy - cat | cat - queen | cat - tom | kitten - feline leukaemia virus | disease caused by

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - pertussis toxoid; filamentous haemagglutinin; pertactin; diphtheria toxoid; tetanus toxoid; polio virus type 1 inactivated; polio virus type 2 inactivated; polio virus type 3 inactivated - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - diphtheria-pertussis-poliomyelitis-tetanus

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Malta - Kiingereza - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - influenza vaccine, split virion, inactivated - suspension for injection - influenza vaccine (split virion, inactivated) 15 µg - vaccines

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

sanofi pasteur - polio virus type 1 inactivated, polio virus type 2 inactivated, polio virus type 3 inactivated - suspension for injection - %v/v - poliomyelitis vaccines

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

sanofi pasteur - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin (fha); pertactin; polio virus type 1 inactivated; polio virus type 2 inactivated; polio virus type 3 inactivated; adsorbed aluminium phosphate; adsorbed fimbriae types 2 + 3 - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-pertussis-poliomyelitis-tetanus

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.